Ongoing Clinical Trials

Banner Sun Health Research Institute conducts many trials and studies, but most commonly we conduct:

• Parkinson's disease trials
• Alzheimer's studies

Below is a list of some of our ongoing clinical trials. To get more information about clinical trials, please call (623) 832-6500. Other trials can also be found online at Centerwatch.com.

If you are interested participating in one of the many clinical trials at Banner Health, please complete the form here.

The Brain and Body Donation Program is looking for patients with a diagnosis of Parkinson's, Alzheimer's disease, dementia with Lewy bodies or REM sleep behavior disorder. To learn more, see Brain and Body Donation below or contact us at (623) 832-6500.

Parkinson's Disease Trials

• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA) ( NCT04777331)
• PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI) (NCT04477785)
• A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease (NCT04154072)
• A Validation Study to Assess the Validity, Measurement Responsiveness, & Reliability of the Parkinson’s Disease Functional Impacts Digital Instrument (PD-FIDI) in Patients with Parkinson’s Disease (PD) with or without Glucocerebrosidase (GBA) Mutations

Alzheimer's Disease Trials

• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE) (NCT05256134)
• A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) ( TAUgether) (NCT04867616)
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ) ( NCT05026177) 
• Assessing Clinical Outcomes in Alzheimer's Disease Agitation (ACCORD) (NCT04797715)
• Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3) Protocol (NCT02854033)
• Escitalopram for Agitation in Alzheimer's Disease (S-CitAD) (NCT 03108846)
• TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD) (NCT 04004767)
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (NCT 04468659)
• Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS) (NCT 03507257)
• ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD) (NCT 04488419)
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4) (NCT04770220) 
• A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD (VIVA-MIND) (NCT03919162)
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (NCT04777396)
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (NCT04777409)

Lewy Body Dementia

• Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (COG1201) (NCT05225415)